Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
Anonymous. Global surveillance and control of hepatitis C.
Report of a WHO Consultation.
Viral Hepatitis, 6 (1999), pp. 35-47
[2.]
Anonymous. EASL International Consensus Conference on Hepatitis C.
Hepatol, 30 (1999), pp. 956-961
[3.]
Anonymous. National institutes of health consensus development conference panel statement. Management of hepatitis C.
Hepatology, 26 (1997), pp. 28-108
[4.]
J.G. McHutchison, S.C. Gordon, E.R. Schiff, M.L. Shiffman, W.M. Lee, V.K. Rustgi, et al.
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.
N Engl J Med, 339 (1998), pp. 1485-1492
[5.]
T. Poynard, P. Marcellin, S.S. Lee, C. Niederau, G.S. Minuk, G. Ideo, et al.
Randomised trial of interferon a2b plus ribavirin for 48 weeks or 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus.
Lancet, 352 (1998), pp. 1426-1432
[6.]
O. Reichard, G. Norkrans, A. Fryden, J.H. Braconier, A. Sonnerborg, O. Weiland.
Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.
Lancet, 351 (1998), pp. 1660-1664
[7.]
T. Poynard, J. McHutchison, Z. Goodman, M-H Ling, J. Albrecht.
Is an «a la carte» combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?.
Hepatology, 31 (2000), pp. 211-218
[8.]
D.T.Y. Lau, D.E. Kleiner, M.G. Ghany, Y. Park, P. Scmid, J.H. Hoofnagle.
10-year follow-up after interferon-α therapy for chronic hepatitis C.
Hepatology, 28 (1998), pp. 1121-1127
[9.]
P. Marcellin, N. Boyer, A. Gervais, M. Martinot, M. Pouteau, C. Castelnau, et al.
Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
Ann Intern Med, 127 (1997), pp. 875-881
[10.]
O. Reichard, H. Glaumann, A. Fryden, G. Norkrans, R. Wejstal, O. Weiland.
Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon.
J Hepatol, 30 (1999), pp. 783-787
[11.]
P.F. Renault, J.H. Hoofnagle.
Side effects of alpha interferon.
Semin liver Dis, 9 (1989), pp. 273-277
[12.]
P. Glue, R. Rouzier-Panis, C. Raffanel, R. Sabo, S.K. Gupta, M. Salfi, et al.
A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C.
Hepatology, 32 (2000), pp. 647-653
[13.]
Taplaz, M, Cortes J, O'Brien S, Keating M, Files F, Rose E et al. Phase I study of polyethylene gycol (PEG) interferon alpha-2b (Introm A) in CML [resumen]. Blood; 92 (Supl): 251
[14.]
P. Glue, J.W.S. Fang, R. Sabo, R. Rouzier-Panis, C. Raffanel, R. Sabo, et al.
PEG-Interferon alfa-2b: pharmacokinetics, pharmakodynamics, safety and preliminary efficacy data.
Hepatology, 30 (1999), pp. 189
[15.]
S. Zeuzem, V. Feinman, J. Rasenck, J. Heatchote, M-YL Lai, E. Gane, et al.
Peginterferon alfa-2a in patients chronic hepatitis C.
N Engl J Med, 343 (2000), pp. 1666-1672
[16.]
C. Trepo, K. Lindsay, C. Niederau, M. Schiffman, S. Gordon, J. Hoefs, et al.
Pegylated interferon alfa-2b (PEG-INTRON) monotherapy is superior to interferon alfa-2b (INTRON A) for the treatment of chronic hepatitis C [resumen].
J Hepatol, 32 (2000), pp. 29
[17.]
E.J. Heatchote, M.L. Shiffman, W. Graham, E. Cooksley, G. Dusheiko, S.S. Lee, et al.
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
N Engl J Med, 343 (2000), pp. 1673-1680
[18.]
Y. Imai, S. Kawata, S. Tamura, I. Yabuuchi, S. Noda, M. Inada, et al.
Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C.
Ann Intern Med, 129 (1998), pp. 94-99
[19.]
S. Nishiguchi, T. Kuroki, S. Nakatani, H. Morimoto, T. Takeda, S. Nakajima, et al.
Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.
Lancet, 346 (1995), pp. 1051-1055
[20.]
D.C. Valla, M. Chevallier, P. Marcellin, J.L. Payen, C. Trepo, M. Fonck, et al.
Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment.
Hepatology, 29 (1999), pp. 1870-1875
[21.]
S. Nishiguchi, S. Shiomi, S. Nakatani, T. Takeda, K. Fukuda, A. Tamori, et al.
Prevention of hepatocelullar carcinoma in patients with chronic active hepatitis C and cirrhosis.
Lancet, 357 (2001), pp. 196-197
[22.]
V. Baffis, I. Shrier, A.H. Sherker, A. Szilagyi.
Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection.
Ann Intern Med, 131 (1999), pp. 696-701
[23.]
D. Murphy, K.M. Detjen, M. Welzel, B. Wiedenmann, S. Rosewick.
Interferon alfa delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases.
Hepatology, 33 (2001), pp. 346-356
[24.]
M. Manns, J.C. McHutchison, S. Gorgon, V.K. Rustgi, M. Shiffman, R. Reindollar, et al.
Peginterferon alfa 2b plus ribavirin compared to interferon alfa2b plus ribavirin for the treatment of chronic hepatitis C: results of randomised trial.
The Lancet, (2001),
[25.]
N.P. Lam, A.U. Neumann, D.R. Gretch, T.E. Wiley, A.S. Perelson, T.J. Layden.
Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa.
Hepatology, 26 (1997), pp. 226-231
[26.]
S. Zeuzem, J.H. Lee, A. Franke, B. Ruster, O. Prummer, et al.
Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa.
Hepatology, 27 (1998), pp. 1149-1156
[27.]
F.C. Bekkering, J.T. Brouwer, G. Leroux-Roels, H. Van Vlierberghe, A. Elewaut, S.W. Schalm.
Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy.
J Hepatol, 28 (1998), pp. 960-964
[28.]
S. Zeuzem, J.M. Schmidt, J.H. Lee, M. Von Wagner, G. Teuber, W.K. Roth.
Hepatitis C dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.
Hepatology, 28 (1998), pp. 245-252
[29.]
S. Zeuzem.
Clinical implications of hepatitis C viral kinetics.
J Hepatol, 31 (1999), pp. 61-64
[30.]
T.J. Layden.
Principles of interferon induction therapy.
Am J Med, 27 (1999), pp. S712-S773
[31.]
F.C. Bekkering, C. Stalgis, J.G. McHutchison, J.T. Brouwer, A.S. Perelson.
Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model.
Hepatology, 33 (2001), pp. 419-423
[32.]
G.L. Davis, R. Esteban-Mur, V. Rustgi, J. Hoefs, S.C. Gordon, C. Trepo, et al.
Interferon alfa2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C.
N Engl J Med, 339 (1998), pp. 1493-1499
[33.]
V. Di Marco, P. Almasio, A. Vaccaro, D. Ferraro, P. Parisi, M.G. Cataldo, et al.
Combined treatment of relapse of chronic hepatitis C with high-dose α2b interferon plus ribavirin for 6 or 12 months.
J Hepatol, 33 (2000), pp. 456-462
[34.]
S. Brillanti, J. Garson, M. Foli, K. Whitby, R. Deaville, C. Masci, et al.
A pilot study of combination therapy with ribavirin plus interferon for interferon -resistant chronic hepatitis C.
Gastroenterology, 107 (1994), pp. 812-817
[35.]
R. Schvarcz, Z.B. Yun, A. Sonnerborg, O. Weiland.
Combination treatment with interferon -2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone.
J Med Virol, 46 (1995), pp. 43-47
[36.]
J. Brouwer, F. Nevens, P. Michielsen.
What options are left when hepatitis C does not respond to interferon? Placebo-controlled Benelux multicentre retreatment trial on ribavirin monotherapy versus combination with interferon.
J Hepatol, 21 (1994), pp. 17A
[37.]
S. Pol, v.s. Ribavirin-interferon.
Interferon (alfa 2b-IFN) alone in non-responders to -2b IFN in chronic hepatitis C.
Hepatology, 24 (1996), pp. A356
[38.]
M. Buti, G. Olive, C. Stalgis, R. Esteban, J. Guardia.
Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C.
Dig Dis Sci, 45 (2000), pp. 1-5
[39.]
A. Bellobuono, L. Mondazzi, S. Tempini, F. Chiodo, E. Magliano, L. Furiano, et al.
Early addition of ribavirin to interferon in chronic hepatitis C not responsive to interferon monotherapy.
J Hepatol, 33 (2000), pp. 463-468
[40.]
Z.M. Younossi, K.D. Mullen, W. Zakko, S. Hodnick, E. Brand, D.S. Barnes, et al.
A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy.
J Hepatol, 34 (2001), pp. 128-133
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
